The median DFS (mDFS) of patients with mesenchymal and tumor positive TRPC3 expression [27.37 m (95%CI = 25.23–29.51)] was significantly shorter than that of patients with double negative expression [34.69 m (95%CI = 28.99–40.38)] (P = 0.006), which indicated that TRPC3 expression in clinical specimens of colorectal cancer patients is related with a poorer prognosis (Fig. 8E). Here, TRPC3 is linked to colorectal cancer.